
“Nanomedicines for drug and gene delivery to the eye”

Dr. Uday B. Kompella
Professor of Pharmaceutical Sciences
Ophthalmology & Bioengineering
University of Colorado Anschutz Medical Campus

Friday, January 13th, 2017
Lecture: 9:00 AM-10:00 AM
ENGINEERING CENTER
ROOM EC 2300
10555 WEST FLAGLER STREET
MIAMI, FL 33174



Abstract: Although the eye is readily accessible for dosing small molecule drug products such as eye drops, only less than 5% of the dose is bioavailable to the ocular tissues, due to multiple static and dynamic barriers. The bioavailability is much less for macromolecules including gene medicines. Nanomedicines provide a unique opportunity to overcome some of the challenges associated with drug and gene delivery to the eye. This presentation will present an overview of drug and gene delivery to the eye and the applicability of nanomedicines.

Biography: Uday B. Kompella, PhD, is a Professor of Pharmaceutical Sciences, Ophthalmology, and Bioengineering at University of Colorado Anschutz Medical Campus. Dr. Kompella's research interests include drug discovery, delivery, and development for treating diseases of the eye including diabetic retinopathy, macular degeneration, and inflammatory eye diseases. Dr. Kompella is a Fellow of the Association for Research in Vision and Ophthalmology (ARVO) and the American Association for Pharmaceutical Scientists (AAPS). He is a recipient of the Dean's Mentoring Award (University of Colorado), Distinguished Scientist Award (University of Nebraska Medical Center), Distinguished Teacher Award (University of Nebraska Medical Center), and Undergraduate Alumni Teaching Excellence Award (Auburn University). Also, he is a recipient of the Carl Camras/Pfizer/ARVO Foundation Translational Research Award in Ophthalmology. He currently serves as the Editor-in-Chief for the journal Expert Opinion on Drug Delivery, Editor for the journal Pharmaceutical Research, and Associate Editor for the Journal of Ocular Pharmacology and Therapeutics. He is a member of the scientific advisory board of the Glaucoma Foundation.